New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
08:25 EDTABBV, ABBV, AET, AET, AMGN, AMGN, ESRX, ESRX, HSP, HSP, MNTA, MNTA, PFE, PFEFTC to hold a workshop
The Biologics Workshop explores competition issues involving biologic medicines and follow-on biologics with a focus on the potential impact of state regulations affecting competition. Companies participating include AbbVie, Aetna, Amgen, Express Scripts, Hospira, Momenta Pharmaceuticals and Pfizer at the FTC Washington, D.C. offices on February 4 at 8:30 am. Webcast Link
News For ABBV;AET;AMGN;ESRX;HSP;MNTA;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
January 22, 2015
11:52 EDTMNTAMomenta sell-off provides good entry point, says Brean Capital
Subscribe for More Information
11:23 EDTPFEPfizer says CHMP adopted positive opinion on Prevenar 13 expansion
Subscribe for More Information
January 21, 2015
12:30 EDTPFEGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
10:28 EDTESRXLeerink pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
10:16 EDTAMGNLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.
10:01 EDTESRXOn the Fly: Analyst Initiation Summary
Subscribe for More Information
08:38 EDTMNTAMomenta announces Supreme Court decision to remand generic Copaxone back to CAFC
Subscribe for More Information
07:36 EDTESRXExpress Scripts initiated with an Equal Weight at Stephens
Subscribe for More Information
January 20, 2015
10:40 EDTMNTAMomenta Pharma sinks after Supreme Court rules on Copaxone
Subscribe for More Information
06:44 EDTESRXExpress Scripts downgraded to Neutral from Buy at UBS
Subscribe for More Information
January 18, 2015
17:40 EDTAETAetna customers can switch coverage after mistake, Bloomberg says
Aetna is being investigated by the U.S. for misleading elderly and disabled people about which pharmacies would fill prescriptions in Medicare drug plans the health insurer sold them, says Bloomberg. According to the Bloomberg report, customers will be able to quit their coverage and choose a new plan this year as a result. Raymond Thorn, a spokesman for the Centers for Medicare and Medicaid Services said Aetna may be fined or prohibited from enrolling new Medicare customers if the agency determines it intentionally misled Medicare patients, added Bloomberg. Reference Link
January 16, 2015
14:54 EDTAETGilead at high of day, up 3% after reaching hep C drug pact with Aetna
14:46 EDTAETAetna, Gilead confirm discount pricing for hepatitis C drugs Harvoni, Sovaldi
Subscribe for More Information
10:47 EDTAETBofA/Merrill healthcare facilities analyst analyst/industry conference call
Healthcare Facilities & Managed Care Analyst Bressler discusses the legislative and regulatory outlook for the industry for 2015 on an Analyst/Industry conference call to be held on January 23 at 2 pm.
10:10 EDTABBVAbbVie announces FDA approval of DUOPA enteral suspension
Subscribe for More Information
07:04 EDTABBVEnanta says EU grants marketing authorizations for AbbVie's Viekirax
Subscribe for More Information
05:05 EDTABBVAbbVie granted marketing authorization by EC for VIEKIRAX + EXVIERA
AbbVie announced that the European Commission has granted marketing authorizations for its all-oral, short-course, interferon-free treatment of VIEKIRAX + EXVIERA. The treatment has been approved with or without ribavirin for patients with genotype 1 chronic hepatitis C virus infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients.1,2 Additionally, VIEKIRAX has been approved for use with RBV in genotype 4 chronic hepatitis C patients.
January 15, 2015
16:04 EDTAMGNAmgen announces new data from Phase 2 PEAK, Phase 3 PRIME studies
Amgen announced new data from the Phase 2 PEAK and Phase 3 PRIME studies that support the first-line use of Vectibix in combination with Folfox, an oxaliplatin-based chemotherapy regimen, in patients with wild-type RAS metastatic colorectal cancer. In an exploratory analysis from the PEAK study, treatment with Vectibix compared to Avastin resulted in a "significantly higher proportion" of patients with earlier tumor shrinkage at week eight, 64% vs. 45%, respectively, and among responding patients, a longer duration of response, 11.4 vs. 8.5 months, respectively, and greater depth of response . Overall response rates appeared to be similar between Vectibix and Avastin. This is consistent with observed overall survival and progression-free survival (PFS) rates, and with data previously reported, Amgen said. It added, "While the primary analysis from PEAK showed similar ORR between the Vectibix- and bevacizumab-based regimens, this exploratory analysis demonstrates that Vectibix produces early, sustained anti-tumor activity, which may in part explain the OS and PFS benefits seen with Vectibix versus bevacizumab in this trial."
11:20 EDTPFE, ABBVGoldman cuts J&J to sell citing competitive pressures
Subscribe for More Information
07:59 EDTPFE, AMGNAmerican Society of Clinical Oncology to hold a symposium
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use